Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147))

Christopher G. Willett, Yves Boucher, Emmanuelle Di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. ChenPaul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain

Research output: Contribution to journalComment/debate

9 Scopus citations
Original languageEnglish (US)
Number of pages1
JournalNature medicine
Volume10
Issue number6
DOIs
StatePublished - Jun 2004

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., Mino, M., Cohen, K. S., Scadden, D. T., Hartford, A. C., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A. X., Blaszkowsky, L. S., ... Jain, R. K. (2004). Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)). Nature medicine, 10(6). https://doi.org/10.1038/nm0604-649c